IDEAYA Biosciences Inc. (IDYA) has announced positive clinical data from the 30 mg expansion dose of its phase II trial of IDE397 monotherapy in methylthioadenosine phosphorylase-deletion urothelial and non-small cell lung cancer patients.
Among the 18 evaluable patients in the trial, the Overall Response Rate was 39% and the Disease Control Rate was about 94%. Furthermore, tumor shrinkage was observed in approximately 78% of patients (14 out of 18), and the ctDNA molecular response rate was an impressive 81%, according to the company.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.